FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999778859> ?p ?o ?g. }

• W1999778859 endingPage "42" @default.
• W1999778859 startingPage "42" @default.
• W1999778859 abstract "Abstract Background: Three prior Phase III trials (E2100, AVADO, and RIBBON-1) established the clinical benefit of adding bevacizumab (BV) to various chemotherapies (chemos) as first-line treatment for metastatic breast cancer (MBC). A previous Phase III study (AVF2119g) in patients with predominantly heavily pre-treated MBC, in which BV was added to capecitabine (Cape), resulted in a significant increase in objective response rate (ORR), but did not meet the primary endpoint for progression-free survival (PFS). The current study, RIBBON-2, was designed to evaluate the efficacy and safety of the addition of BV to chemotherapies used as second-line treatment for MBC.Methods: Patients were randomized in a 2:1 ratio to chemo+BV or chemo+placebo (PL). Key eligibility criteria included one prior cytotoxic treatment for MBC, ECOG performance status of 0 to 1, and HER2-negative or unknown status. Prior to randomization, investigators chose one of the following chemo agents: taxane (T; paclitaxel 90 mg/m2/wk for 3 of the 4 weeks; paclitaxel 175 mg/m2, nab-paclitaxel 260 mg/m2, docetaxel 75–100 mg/m2, all given q3wk), gemcitabine (G; 1250 mg/m2 on Days 1 and 8 q3wk), Cape (2000 mg/m2 Days 1–14 q3wk), or vinorelbine (V; 30 mg/m2/wk). BV or PL was administered at 10 mg/kg q2wk or 15 mg/kg q3wk, depending on the chemo regimen. The primary endpoint of the study was investigator-assessed PFS pooled across the chemo cohorts. Key secondary endpoints included overall survival (OS), PFS within individual chemo cohorts, ORR, and safety.Results: 684 patients (T, 304; G, 160; Cape, 144; and V, 76) at 211 sites in 19 countries were randomized between February 2006 and June 2008. Overall, the two study arms were balanced for patient characteristics at baseline. The study met its primary endpoint of PFS pooled across chemo cohorts and also demonstrated a 10% increase in ORR when BV was added to chemo. At the interim analysis for OS, the median durations were 18 mo for chemo+BV and 16.4 mo for chemo+PL (see table).Across all chemo cohorts the incidence of BV-related AEs was consistent with data from previous studies. Hypertension was the only BV-related AE consistently increased in the chemo+BV arm across all chemo cohorts.Conclusions: The addition of BV to chemotherapies used for second-line treatment of MBC led to a significant improvement in PFS. The AE profile of BV in the overall study population and across the chemotherapy cohorts was consistent with that previously observed. Additional analyses, including PFS for the individual chemo cohorts, will be presented. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 42." @default.
• W1999778859 created "2016-06-24" @default.
• W1999778859 creator A5010210187 @default.
• W1999778859 creator A5011868552 @default.
• W1999778859 creator A5035733678 @default.
• W1999778859 creator A5044108002 @default.
• W1999778859 creator A5058350648 @default.
• W1999778859 creator A5065306642 @default.
• W1999778859 creator A5066660345 @default.
• W1999778859 creator A5068059897 @default.
• W1999778859 creator A5081408394 @default.
• W1999778859 creator A5089208460 @default.
• W1999778859 date "2009-12-01" @default.
• W1999778859 modified "2023-09-27" @default.
• W1999778859 title "RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer." @default.
• W1999778859 doi "https://doi.org/10.1158/0008-5472.sabcs-09-42" @default.
• W1999778859 hasPublicationYear "2009" @default.
• W1999778859 type Work @default.
• W1999778859 sameAs 1999778859 @default.
• W1999778859 citedByCount "43" @default.
• W1999778859 countsByYear W19997788592012 @default.
• W1999778859 countsByYear W19997788592013 @default.
• W1999778859 countsByYear W19997788592021 @default.
• W1999778859 crossrefType "journal-article" @default.
• W1999778859 hasAuthorship W1999778859A5010210187 @default.
• W1999778859 hasAuthorship W1999778859A5011868552 @default.
• W1999778859 hasAuthorship W1999778859A5035733678 @default.
• W1999778859 hasAuthorship W1999778859A5044108002 @default.
• W1999778859 hasAuthorship W1999778859A5058350648 @default.
• W1999778859 hasAuthorship W1999778859A5065306642 @default.
• W1999778859 hasAuthorship W1999778859A5066660345 @default.
• W1999778859 hasAuthorship W1999778859A5068059897 @default.
• W1999778859 hasAuthorship W1999778859A5081408394 @default.
• W1999778859 hasAuthorship W1999778859A5089208460 @default.
• W1999778859 hasConcept C121608353 @default.
• W1999778859 hasConcept C126322002 @default.
• W1999778859 hasConcept C142724271 @default.
• W1999778859 hasConcept C143998085 @default.
• W1999778859 hasConcept C168563851 @default.
• W1999778859 hasConcept C203092338 @default.
• W1999778859 hasConcept C204787440 @default.
• W1999778859 hasConcept C27081682 @default.
• W1999778859 hasConcept C2775930923 @default.
• W1999778859 hasConcept C2776694085 @default.
• W1999778859 hasConcept C2777063308 @default.
• W1999778859 hasConcept C2777292972 @default.
• W1999778859 hasConcept C2777511904 @default.
• W1999778859 hasConcept C2777802072 @default.
• W1999778859 hasConcept C2777909004 @default.
• W1999778859 hasConcept C2778239845 @default.
• W1999778859 hasConcept C2780258809 @default.
• W1999778859 hasConcept C2780350996 @default.
• W1999778859 hasConcept C2780739268 @default.
• W1999778859 hasConcept C2781190966 @default.
• W1999778859 hasConcept C2781413609 @default.
• W1999778859 hasConcept C31760486 @default.
• W1999778859 hasConcept C526805850 @default.
• W1999778859 hasConcept C530470458 @default.
• W1999778859 hasConcept C61943457 @default.
• W1999778859 hasConcept C71924100 @default.
• W1999778859 hasConceptScore W1999778859C121608353 @default.
• W1999778859 hasConceptScore W1999778859C126322002 @default.
• W1999778859 hasConceptScore W1999778859C142724271 @default.
• W1999778859 hasConceptScore W1999778859C143998085 @default.
• W1999778859 hasConceptScore W1999778859C168563851 @default.
• W1999778859 hasConceptScore W1999778859C203092338 @default.
• W1999778859 hasConceptScore W1999778859C204787440 @default.
• W1999778859 hasConceptScore W1999778859C27081682 @default.
• W1999778859 hasConceptScore W1999778859C2775930923 @default.
• W1999778859 hasConceptScore W1999778859C2776694085 @default.
• W1999778859 hasConceptScore W1999778859C2777063308 @default.
• W1999778859 hasConceptScore W1999778859C2777292972 @default.
• W1999778859 hasConceptScore W1999778859C2777511904 @default.
• W1999778859 hasConceptScore W1999778859C2777802072 @default.
• W1999778859 hasConceptScore W1999778859C2777909004 @default.
• W1999778859 hasConceptScore W1999778859C2778239845 @default.
• W1999778859 hasConceptScore W1999778859C2780258809 @default.
• W1999778859 hasConceptScore W1999778859C2780350996 @default.
• W1999778859 hasConceptScore W1999778859C2780739268 @default.
• W1999778859 hasConceptScore W1999778859C2781190966 @default.
• W1999778859 hasConceptScore W1999778859C2781413609 @default.
• W1999778859 hasConceptScore W1999778859C31760486 @default.
• W1999778859 hasConceptScore W1999778859C526805850 @default.
• W1999778859 hasConceptScore W1999778859C530470458 @default.
• W1999778859 hasConceptScore W1999778859C61943457 @default.
• W1999778859 hasConceptScore W1999778859C71924100 @default.
• W1999778859 hasIssue "24_Supplement" @default.
• W1999778859 hasLocation W19997788591 @default.
• W1999778859 hasOpenAccess W1999778859 @default.
• W1999778859 hasPrimaryLocation W19997788591 @default.
• W1999778859 hasRelatedWork W1999778859 @default.
• W1999778859 hasRelatedWork W2051530062 @default.
• W1999778859 hasRelatedWork W2062043136 @default.
• W1999778859 hasRelatedWork W2073443344 @default.
• W1999778859 hasRelatedWork W2085123446 @default.
• W1999778859 hasRelatedWork W2272679456 @default.
• W1999778859 hasRelatedWork W2410831480 @default.
• W1999778859 hasRelatedWork W2468666928 @default.

• next